
Baudax Bio Announces $17.6 Million Offering
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that it has entered into a definitive agreement with institutional and …
Read More